Escamilla Gómez, VirginiaGarcía-Gutiérrez, ValentínLópez Corral, LucíaGarcía Cadenas, IrenePérez Martínez, AriadnaMárquez Malaver, Francisco JCaballero-Velázquez, TeresaGonzález Sierra, Pedro AViguria Alegría, María CParra Salinas, Ingrid MCalderón Cabrera, CristinaGonzález Vicent, MartaRodríguez Torres, NancyParody Porras, RocíoFerra Coll, ChristelleOrti, GuillermoValcárcel Ferreiras, DavidDe la Cámara LLanzá, RafaelMolés, PaulaVelázquez-Kennedy, KyraJoão Mende, MaríaCaballero Barrigón, DoloresPérez, EstefaníaMartino Bofarull, RodrigoSaavedra Gerosa, SilvannaSierra, JorgePoch, MarcZudaire Ripa, María TDíaz Pérez, Miguel AMolina Angulo, BlancaSánchez Ortega, IsabelSanz Caballer, JaimeMontoro Gómez, JuanEspigado Tocino, IldefonsoPérez-Simón, José AGrupo Español de Trasplante Hematopoyético (GETH)2023-02-082023-02-082019-11-07http://hdl.handle.net/10668/14653Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1-5) previous lines of therapy. Overall response rate was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21.7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1-10). Overall response rate was 57.1% (32/56) with 3.5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57.1%) groups. Overall survival was 47% (CI: 23-67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63-89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Acute DiseaseChronic DiseaseGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansNitrilesPyrazolesPyrimidinesRetrospective Studiesresearch article31700138open access10.1038/s41409-019-0731-x1476-5365PMC7051903https://www.nature.com/articles/s41409-019-0731-x.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051903/pdf